タンパク質構造変化の測定によりアルツハイマー病の新規バイオマーカー群を確立(Study measuring changes in protein structure establishes new class of Alzheimer’s biomarkers)

ad

2026-02-27 米国国立衛生研究所(NIH)

米国国立衛生研究所(NIH)主導の研究は、血液中タンパク質の「構造変化」を測定することで、アルツハイマー病の新たなバイオマーカー群を確立した。従来はアミロイドβやタウの量的変化が中心だったが、本研究はタンパク質の折り畳み構造の異常に着目。高度な質量分析技術を用いて血漿中タンパク質の立体構造変化を網羅的に解析し、発症前段階から検出可能な指標を特定した。これにより、より早期かつ非侵襲的な診断や進行予測が可能となる可能性が示された。成果はアルツハイマー病の病態理解を深め、創薬や個別化医療への応用が期待される。

<関連情報>

血漿タンパク質の構造特性がアルツハイマー病の状態を分類する Structural signature of plasma proteins classifies the status of Alzheimer’s disease

Ahrum Son,Hyunsoo Kim,Jolene K. Diedrich,Casimir Bamberger,Heather M. Wilkins,Jeffrey M. Burns,Jill K. Morris,Robert A. Rissman,Russell H. Swerdlow & John R. Yates III
Nature Aging  Published:27 February 2026
DOI:https://doi.org/10.1038/s43587-026-01078-2

タンパク質構造変化の測定によりアルツハイマー病の新規バイオマーカー群を確立(Study measuring changes in protein structure establishes new class of Alzheimer’s biomarkers)

Abstract

Alzheimer’s disease (AD) involves proteostasis dysregulation causing protein misfolding, but whether these structural changes manifest as plasma conformational biomarkers remains unclear. We profiled plasma protein structures from 520 participants including individuals with AD, individuals with mild cognitive impairment (MCI) and healthy controls. Using mass spectrometry and machine learning, we systematically characterized the structural proteome changes associated with ApoE variations and neuropsychiatric symptoms to identify AD-specific signatures. We developed a diagnostic panel using peptides from C1QA, CLUS and ApoB representing AD-associated structural changes. This three-marker panel achieved 83.44% accuracy in three-way classification (healthy versus MCI versus AD). Binary classification yielded area under the receiver operating characteristic curves of 0.9343 for healthy versus MCI and 0.9325 for MCI versus AD. Longitudinal samples were classified with 86.0% accuracy. This multi-marker panel based on plasma protein structural alterations represents a promising diagnostic approach that may enhance early AD detection and provide insights for clinical trials, improving therapeutic outcomes.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました